Two bioengineering professors named AIMBE fellows

Bioengineering professors Jennifer Amos and Sergei Maslov have been named fellows of the American Institute for Medical and Biological Engineering (AIMBE).

Amos was honored for her outstanding contributions to the development of curriculum and assessment methods in biomedical engineering and engineering-driven medical education. Maslov was recognized for his contributions to computational biology including microbiome dynamics, microbial and viral ecology, genomics, and studies of complex biological networks. Both professors have also been actively involved in efforts across the biomedical engineering community during the COVID-19 pandemic. 

The College of Fellows is comprised of the top two percent of medical and biological engineers in the country. The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs comprise the College of Fellows. AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Nobel Prize, the Presidential Medal of Science and the Presidential Medal of Technology and Innovation and many also are members of the National Academy of Engineering, National Academy of Medicine, and the National Academy of Sciences.

A formal induction ceremony will be held during AIMBE’s 2021 Annual Event on March 26 where Amos and Maslov will be inducted along with 174 colleagues who make up the AIMBE Fellow Class of 2021. 

--

About AIMBE

AIMBE’s mission is to recognize excellence in, and advocate for, the fields of medical and biological engineering in order to advance society. Since 1991, AIMBE’s College of Fellows has led the way for technological growth and advancement in the fields of medical and biological engineering. AIMBE Fellows have helped revolutionize medicine and related fields to enhance and extend the lives of people all over the world. They have successfully advocated for public policies that have enabled researchers and business-makers to further the interests of engineers, teachers, scientists, clinical practitioners, and ultimately, patients.